Post

P-MUC1C-ALLO1 by Poseida Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to …

P-MUC1C-ALLO1 by Poseida Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to …

P-MUC1C-ALLO1 by Poseida Therapeutics for Pancreatic Cancer: Likelihood of Approval

P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase …

ZB-131 by ZielBio for Ovarian Cancer: Likelihood of Approval

ZB-131 is under clinical development by ZielBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II …

Sudocetaxel zendusortide by Theratechnologies for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Sudocetaxel zendusortide is under clinical development by Theratechnologies and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to …